Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence
People living with sickle cell disease (SCD) face intermittent acute pain episodes due to vaso-occlusion primarily treated palliatively with opioids. Hemolysis of sickle erythrocytes promotes release of heme, which activates inflammatory cell adhesion proteins on endothelial cells and circulating ce...
Main Authors: | Thomas Gentinetta, John D. Belcher, Valérie Brügger-Verdon, Jacqueline Adam, Tanja Ruthsatz, Joseph Bain, Daniel Schu, Lisa Ventrici, Monika Edler, Hadi Lioe, Kalpeshkumar Patel, Chunsheng Chen, Julia Nguyen, Fuad Abdulla, Ping Zhang, Andreas Wassmer, Meena Jain, Marcel Mischnik, Matthias Pelzing, Kirstee Martin, Roslyn Davis, Svetlana Didichenko, Alexander Schaub, Nathan Brinkman, Eva Herzog, Adrian Zürcher, Gregory M. Vercellotti, Gregory J. Kato, Gerald Höbarth |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/3/630 |
Similar Items
-
Hemopexin and Cancer
by: Veronica Fiorito, et al.
Published: (2022-01-01) -
Human Plasma and Recombinant Hemopexins: Heme Binding Revisited
by: Elena Karnaukhova, et al.
Published: (2021-01-01) -
Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome
by: Agnieszka Pukajło-Marczyk, et al.
Published: (2021-07-01) -
New Insights into Hemopexin-Binding to Hemin and Hemoglobin
by: Guilherme C. Lechuga, et al.
Published: (2022-03-01) -
Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders.
by: Ann eSmith, et al.
Published: (2015-06-01)